Previous close | 52.03 |
Open | 51.00 |
Bid | 49.80 x 200 |
Ask | 49.93 x 400 |
Day's range | 49.21 - 51.51 |
52-week range | 14.42 - 55.26 |
Volume | |
Avg. volume | 1,044,966 |
Market cap | 2.902B |
Beta (5Y monthly) | 1.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.36 |
Earnings date | 02 Aug 2024 - 06 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 45.90 |
We can readily understand why investors are attracted to unprofitable companies. Indeed, Twist Bioscience ( NASDAQ:TWST...
Here is how DaVita HealthCare (DVA) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
SOUTH SAN FRANCISCO, Calif., June 06, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy. The study titled, "Discovery of a potent, selective, and tumor-suppressing